2,622 Shares in AstraZeneca PLC $AZN Bought by 1ST Source Bank

1ST Source Bank bought a new stake in AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,622 shares of the company’s stock, valued at approximately $201,000.

A number of other hedge funds have also made changes to their positions in the company. Fayez Sarofim & Co grew its stake in AstraZeneca by 173.4% in the 2nd quarter. Fayez Sarofim & Co now owns 3,745,902 shares of the company’s stock valued at $261,764,000 after acquiring an additional 2,376,032 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of AstraZeneca by 2,389.9% in the second quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock valued at $142,798,000 after purchasing an additional 1,961,764 shares in the last quarter. Raymond James Financial Inc. grew its position in shares of AstraZeneca by 64.8% in the second quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after purchasing an additional 1,487,662 shares during the last quarter. Ontario Teachers Pension Plan Board purchased a new position in shares of AstraZeneca during the 2nd quarter worth approximately $96,936,000. Finally, JPMorgan Chase & Co. raised its position in shares of AstraZeneca by 27.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,824,072 shares of the company’s stock worth $370,103,000 after purchasing an additional 1,048,738 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN opened at $208.72 on Friday. The company has a 50-day moving average of $135.91 and a two-hundred day moving average of $102.01. The stock has a market cap of $323.71 billion, a price-to-earnings ratio of 69.34, a PEG ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. AstraZeneca PLC has a one year low of $122.48 and a one year high of $212.71.

AstraZeneca Dividend Announcement

The company also recently announced a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be paid a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s payout ratio is 74.83%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on AZN shares. Morgan Stanley reiterated an “overweight” rating and set a $103.00 target price on shares of AstraZeneca in a report on Wednesday, December 3rd. Wall Street Zen downgraded AstraZeneca from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. HSBC reiterated a “buy” rating and set a $108.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Finally, Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.